Kye Pharmaceuticals Announces the Availability of Dyanavel® XR Tablets Across Canada for the Treatment of ADHD

MISSISSAUGA, ON, June 8, 2026 /PRNewswire/ - Kye Pharmaceuticals Inc. ("Kye"), a Canadian-based specialty pharmaceutical company focused on licensing and commercializing innovative medicines for patients in Canada, today announced that Dyanavel® XR (amphetamine extended-release) tablets...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.